facility: concord hospital · induced by ttp-based cationic lipophilic phosphonium salts (clps) and...

Concord Hospital Research report 2001/2002

Project Project Title

Researchers First Initial, Surname

Funding Origin of Funding

Date Year Funding received

$ Amount

of Funding

Duration Length of project

Brief Description in lay terms of project aims

Anaesthesiology A study to investigate the effects of continuous infiltration with ropivacaine using a commercially available infusion device on postoperative opioid requirements, pain scores and patient mobility

J Smith A Spralja P Hendel

Donation of ropivacaine by Astra Zeneca and OnQ devices by Johnson&Johnson

2000 22 months This is a study to determine whether continuous infusion of ropivacaine for 2-3 days after thoracotomy improved patient comfort and function

Anatomical Pathology/Electron Microscope Unit Molecular pathology of pancreatic cancer

B Lin R L Sutherland et al.

Nil 2002 3 years The aim of this research is to identify novel genes in the development of pancreatic cancer. This will hopefully open a doorway to better treatment and survival of patients with pancreatic cancer

Molecular genetics and immunohistochemical analysis of Stage B colonic carcinomas

B Lin C Chan E L Bokey R Trent M Kohenen-Corish et al.

2 years

Analysis of p53 expression in transitional cell carcinoma

L Hughes L Chan

1 year

Assessment of disease control in chronic airways limitation by sputum eosinophil count

L Hughes S Lim et al.

2 years

Ultrastructural changes induced by TTP-based cationic lipophilic phosphonium salts (CLPS) and chlorpromazine (CPZ)

S Brammah L Wright E Delikatny et al.

NHMRC Leo & Jenny Leukaemia and Cancer Foundation

1996 8 years This research investigates the mechanism of action of two anti-cancer drugs. The ultrastructural changes seen in human breast cancer cell lines with these drugs include alterations to mitochondria and increases in the number of lipid droplets

Mycobacterium as an environmental enhancer of SLE in a mouse model of SLE

C Hawke P Kirwan R van Driel A Baxter

3 years Validation of a mouse model of systemic lupus erythematosus

http://www.cs.nsw.gov.au/AGM/research.htm

Burns Unit The effects of Nandrolone Decanoate on wound healing in major burns: a randomised controlled clinical trial

P Maitz D Handelsman

Nil 2 years The aim of this study is to determine whether androgen therapy improves wound healing and metabolic effects in major burns

Invasive burn wound infection: its relationship to skin graft outcome and sepsis

T Heath P Maitz T Gottlieb

Nil This research aims to examine whether there is an association between biopsy evidence of infection in tissues underneath burned skin and subsequent skin graft survival

The application of cultured epithelial cells to grafts on burns wounds

P Maitz J Sharp

This research will provide the technology to culture skin cells which can be transferred to burn sites during surgery and thus provide replacement skin for patients with severe burns

A Phase IIa clinical evaluation of a topically applied, biologically active, milk-derived extract (B6011A) in the treatment of skin graft donor site wounds

P Maitz R Johnson

GroPep Limited Per patient funding

1 year The aim of this study is to test whether a solution of BG011A is safe and effective in treating skin graft donor site wounds when applied to the donor sites of patients with burns

Pressure garment comparision

M Carne Nil A comparison study between two brands of pressure garments used in the management of hypertrophic scarring following burns

Does splinting effect the incidence of hetertopic ossification at the elbow in burns?

F Li M Carne

Cardiology CHARM A Sindone Astra Zeneca 1999 ~$440

per patient

4 years To evaluate the effectiveness of candesartan in patients with heart failure

EPHESUS A Sindone Searle 2000 ~$3500per

2 ½ years

patient

To determine the effectiveness of eplerenone in increasing the chance of survival from heart failure after a heart attack

2

OVERTURE A Sindone Bristol-Myers

Squibb 1999 ~$8500

per patient

2 years To determine whether omapatrilat is better than enalapril in prolonging survival and delaying the progression of heart failure

ENABLE A Sindone Actelion Ltd. 2000 ~$5500 per patient

2 years To evaluate the effectiveness of bosentan in heart failure patients

CHAT A Sindone Nil Notapplicable

Nil 2 years To determine whether regular telephone contact by heart failure nurse reduces the number and duration of hospital admissions, improves quality of life of patients with heart failure and survival chances

I-PRESERVE A Sindone Bristol-MyersSquibb & Sanofi~synthelabo

2002 ~$8000per patient

4 years To evaluate the effectiveness of irbesartan in heart failure patients with preserved systolic function

PERINDOPRIL A Sindone Servier 2002 ~$250 per patient

9 months To determine the influence of perindopril on diastolic dysfunction and brain natriuretic peptide levels in heart failure patients with preserved systolic function

Accuracy of Coronary CT angiography

G Lau L Kritharides L Ridley D Brieger

Cardiology trust fund

2002 $12,540 1 year per annum

To compare CT (computer tomography) angiography with conventional coronary angiography

CABG-Risk Study G Lau L Kritharides D Sullivan L Ridley P Bannon D Brieger

Cardiology trust fund

2002 3 years To identify the risk factors associated with coronary vein graft disease using serial CT (computer tomography) angiography and blood and clinical markers

Liver Dysfunction in Heart Failure

G Lau H Tan L Kritharides

nil - This study aims to identify the typical pattern of Liver Function test abnormalities in heart failure and to correlate these with echocardiographic parameters

C-Reactive Protein (CRP) and thrombus in unstable angina

S Chandar R Walls S B Freedman

nil 2001-02 2 years This study will relate the presence of CRP-induced coagulant activity on blood monocytes with measurements of immune activation in patients with angina pectoris

C-Reactive Protein (CRP) and vascular injury

G Lau S Riminton S B Freedman

nil - This study aims to document the changes in CRP after vascular injury and the effect of medications on CRP levels

3

SPORTIF D Brieger

M Hayes Astra Zeneca 2000-02 $60 000

in 2001 2 years This study aimed to show whether a new

anticoagulant was safer and more effective than warfarin in patients with atrial fibrillation

GRACE D Brieger Aventis 1999 $100 perpatient

5 years A multinational, prospective, observational registry to define patient demographics, presentation characteristics, management, and hospital and post-discharge outcomes of patients hospitalised with suspected Acute Coronary Events (ACE)

Synergy D Brieger Aventis 2002 $3,400per patient

2 years The aim of this study is to determine if Enoxaparin is superior to unfractionated heparin in high-risk patients with acute coronary syndromes managed with a strategy of early, invasive treatment

Alternate mediators of fibrinolysis in plasminogen knock-out mice

D Brieger D Bruce B Zeng S B Freedman

Concord Cardiology Trust Fund NHMRC PhD scholarship

1999 2000

$50, 000 per annum $16, 135 per annum

3 years 3 years

The aim of this project is to identify enzymes which break down blood clots in mice that lack plasminogen (the normal major enzyme for clot breakdown)

CERA (Centre for Education and Research on Ageing) Hepatic oxygenation and ageing

D Le Couteur A McLean A Ansselin

NHMRC (project grant)

1999-2001 $165,000 3 years A study of the effects of ageing on the structure and function of the ageing liver, using technologies including electron microscopy, magnetic resonance spectroscopy, immunohistochemistry, perfused liver preparations and human pharmacokinetic studies

Pathogenesis and functional significance of age-related pseudocapillarisation

D Le Couteur SESQUI, The University of Sydney

2001 $42,500 1 year Characterisation of age-related changes in the vascular system in the liver using immunohistochemistry and perfused liver method

Scoping study on ageing research

D Le Couteur Z Khalil G Andrews J Kril et al.

NHMRC Tender 2001 $82,000 1 year A review of ageing research in Australia

Falls prevention in residential care

D Le Couteur C Shanley et al.

Dept of Health and Aged Care

2001 $155,000 1 year Identification and implementation of best practice for managing falls in older people in residential care

4

Purchase of HPLC D Le Couteur NHMRC Equipment

grant, The University of Sydney

2001 $18,000 1 year Study of the effects of ageing on hepatic drug metabolism

A potential new test for diagnosing early dopamine cell loss

K Double G Halliday D Le Couteur et al

Australian Brain Foundation

2001 $75,000 1 year Development of a new test for the diagnosis of Parkinson’s disease based on antibodies to neuromelanin. Examination of epidemiological risk factors for Parkinson’s disease

Ageing and the liver A McLean D Le Couteur

NHMRC/DVA 2002-2005 $240,000 3 years

Correlates of brain atrophy in Alzheimer’s disease (AD)

J Kril P Waley S Patel F Png

Medical Foundation of The University of Sydney

1997-2001 $810,000 5 years This study investigates the pattern and distribution of brain atrophy in AD and compares it with normal aged subjects. We have shown that the medial temporal lobe and dorsolateral frontal lobe are disproportionately atrophied in AD. Furthermore we have investigated the mechanisms of neuronal degeneration in AD and shown that neurofibrillary tangle formation accounts for only a minor proportion of cell death in AD

Non-Alzheimer dementias: Pathogenesis and clinicopathological correlations

J Kril H Creasey G Halliday M Broe

NHMRC 2001-2003 $435,000 3 years In this study we are investigating the distribution and pathogenesis of neurodegeneration in frontotemporal dementia (FTD). In addition, we are studying subtypes of FTD to establish whether there are pathological differences between these groups

Genetic factors and regional brain atrophy in the diagnosis of dementia with Lewy bodies

G Halliday G A Broe A Harding W S Brooks

NHMRC (grant held by G Halliday at Prince of Wales Medical Research Institute)

2001 2002 2003

$190,000 $190,000 $190,000

3 years This project aims to find genetic factors causing or contributing to dementia with Lewy bodies by seeking secondary cases of dementia or parkinsonism among the families of patients with Lewy body disease confirmed at autopsy. Previous work by Associate Professor Halliday at POWMRI has linked atrophy of a particular brain region known as the cingulate gyrus with dementia with Lewy bodies. This finding will be tested in living subjects by using MRI scans to examine participants from the Sydney Older Persons Study, comparing people with and without dementia

5

NHMRC Network of Brain Research into Mental Disorders (Genetic Linkage Consortium, Diagnostic Assessment Consortium)

C Masters P R Schofield G A Broe H Creasey W S Brooks

NHMRC (grant held by The University of Melbourne)

2001 $36,885 8 years (1994-2001)

This competing unit grant was established to promote interstate and interdisciplinary cooperation to coordinate studies of schizophrenia, bipolar affective disorder and dementia, so that clinical, genetic, neuroimaging and neuropathological aspects of these conditions could be studied in a coordinated manner

Cloning and biochemical characterisation of a new gene that causes Alzheimer's disease

J Kwok P R Schofield W S Brooks

DVA (grant held by the Garvan Institute of Medical Research)

2001 $98,000 3 years (1999-2001)

The aim of this project was to identify the genetic mutation responsible for causing hereditary Alzheimer’s disease in a large extended family from Tasmania which had been ascertained through the activities of the NHMRC Network of Brain Research into Mental Disorders. The mutation has been identified and studied in the laboratory to discover what effect it has on amyloid peptide production, and hence how it might cause Alzheimer’s disease

Clinical Andrology A study of the prostatic contribution of circulating DHT (dihydrotestosterone)

D Handelsman S Kelleher A Conway

Nil 6 months The purpose of the study is to determine how important prostatic 5-α-reductase activity is in overall circulating DHT levels

Long-term pharmacokinetics and clinical efficacy of Andromen Forte 5% Cream for androgen replacement in hypogonadal men


Lawley Pharmaceuticals

2002 $25,000 1 year The aim of the study is to determine: (a) the stability of the pharmacokinetics; (b) confirm maintenance of adequate plasma testosterone concentrations; (c) ascertain the optimal dose; and (d) verify that clinical androgenic efficacy can be sustained over 3 months using once daily topical dermal application of Andromen Forte 5% cream for androgen replacement in men with classical androgen deficiency

Pharmacokinetics of Andromen Forte 5% cream: A dose-finding study


Lawley Pharmaceuticals

2001 $22,000 3 months The aim of the study was to determine the best dose of Andromen Forte 5% cream for the maintenance of circulating levels of testosterone in men with classical androgen deficiency

6

Development of a serum panel to develop normal laboratory ranges when testing for reproductive health in men

D Handelsman P Anderson

Andrology Australia 2002 $27,250 1 year The aim of this study is to develop a panel of blood samples on a defined population of men, that can be used as a reference for laboratories when testing for male reproductive hormones

Efficacy, safety and service feasibility of an androgen/progestin depot regimen for hormonal male contraception

D Handelsman L Turner A Conway

CONRAD 2001-2 $140,000 3 years The aim of this study is to determine if the androgen/progestin depot regimen provides contraceptive efficacy in a form which would be suitable for the provision of a contraceptive service

The effects of Nandrolone Decanoate on rehabilitation and quality of life in men with chronic pain and opioid-induced androgen deficiency: a randomized, placebo-controlled cross-over clinical trial

D Handelsman M Cousins

Nil 2 years The aim is to determine whether androgen therapy improves the quality of life and rehabilitation in men with chronic non cancer pain who have opiate-induced androgen deficiency

A double-blind, placebo controlled randomised crossover study of testosterone on physical activity, sleep and cognition in men over 60 years of age

P Liu D Handelsman R Grunstein

Serono 2001 $32,875 2 years The aim of the study is to determine the benefits of recombinant human Chorionic Gonadotrophin (hCG) as a form of androgen supplementation in ageing men and to examine the potential adverse effects on cardiovascular or prostate disease as well as sleep and sleep breathing

Prenatal Factors in Male Reproductive Health

D Handelsman NHMRC 2001 $95,000 3 year The aim of this research is to establish and study a birth cohort to evaluate prenatal influences on testis and prostate development

Colorectal Unit Population screening for colorectal cancer

L Irwig L Bokey P Chapuis et al.

Commonwealth project grant

2001 $4.95million

3 years The Unit is a designated centre for population screening for bowel cancer in NSW

7

Maintenance of the Colorectal Cancer (CRC) Hospital Registry

L Bokey P Chapuis et al.

1971 -ongoing

This registry contains details of all patients operated on for CRC by surgeons of the Colorectal Unit. The information it contains will help improve the reporting of bowel cancer and aid in the prediction of patient prognosis

Dermatology An open-label study to evaluate the safety and long-term clinical efficacy of Imiquimod cream applied once daily, seven days per week for 6 weeks on the treatment of superficial basal cell carcinoma

E Collins M Piggin J Fegon C Ong

3M Pharmaceuticals

2001 $ 3 115 5 years The aim of this study is to determine whether a cream called Imiquimod is capable of treating superficial skin cancers when applied every day for 6 weeks. Patients are followed up for 5 years

Endocrinology CORE M Hooper Eli Lilly 1999 4 years This is a trial of raloxifene in lowering risk of breast

cancer in postmenopausal women with osteoporosis

GHBQ-PTH M Hooper Eli Lilly 2001 3 years New combination treatment for osteoporosis in women

Alendronate in Paget’s disease

M Hooper Merk, Sharp & Dohme

2001 6 months Comparison of daily tablet vs weekly buffered solution of alendronate for the treatment of Paget’s Disease of the bone

Rio-Lipids study M Hooper Sanofi 2001 1 year A trial of a new drug for weight loss in obese patients with dyslipidaemias

PEARL M Hooper Pfizer 2001 3 years Treatment with lasofoxifene for Postmenopausal Women with Osteoporosis

Lasofoxifene in sexual dysfunction

M Hooper Pfizer 2001 1 year Improvement of Sexual Function in Postmenopausal Women

HMR 1964 in Type1 diabetes

R Chen Aventis 2001 ~ $3,000 per patient

6 months Comparison of a fast-acting insulin with conventional regular insulin, both used in combination with long-acting glargine insulin

8

Extension study: Risedronate in osteoporosis

M Hooper Proctor and Gamble

2002 ~ $5,000 1 year per patient

This is a risedronate-free observational extension of the 7 year trial in postmenopausal women with osteoporosis

Zolodronic acid extension 2

M Hooper Novartis 2002 2 years A safety extension study evaluating iv zolodronic acid in post-menopausal osteoporosis.

Zolodronic Acid in Paget’s Disease

M Hooper Novartis 2001 $4,000 to $7,000 per patient

6 months This is a randomised trial of intravenous zoledronic acid for the treatment of Paget’s Disease of bone using risedronate as a comparator

Risedronate in men M Hooper Aventis/ProctorGamble

2002 $4,000 to$7,000 per patient

2 years A study of a treatment for osteoporosis in men

HMR1964 VS regular human insulin in type 2 diabetes mellitus

R Chen M Hooper T Cromer C Ting N Kormas C Shankley

Aventis 2002 $4,000 to$7,000 per patient

Approx 12 months To assess non inferiority between HMR1964 and regular human insulin in people with type 2 diabetes

Gastroenterology The Caffeine Breath test

G Park M Ngu B Jones P Katelaris D LeCouteur

Gastroenterology Unit CERA NHMRC

2001 $28,000 3 years To determine if the oral 13C-Caffeine Breath Test is a viable quantitative test of liver function: to see if it can differentiate varying degrees of liver impairment and act as a surrogate marker of morbidity and mortality in individuals with liver dysfunction

Immunology Traditional Chinese medicine in treatment of allergic diseases

R Walls G Hu

Taiji- The University of Sydney Research Fund for Traditional Chinese Medicine

1999 $220,000 3 years This study was a randomised trial, which showed that a Chinese herbal formulation for the treatment of allergic rhinitis is effective. The mode of action of the treatment is now being investigated

Medicine FIELD study R Wyndam NHMRC 2000 $86,000 5 years Vascular disease prevention in patients with non-

insulin dependent diabetes using the drug Fenofibrate in a double blind study

9

Microbiology Australian Group for Antimicrobial Resistance (AGAR) – Staph aureus study

T Gottlieb G Funnell

Microbiology Research Trust Fund

- - On-going Multi-centre study (>20 hospitals in all states and territories) to determine trends and prevalence of antibiotic resistance

Australian Group for Antimicrobial Resistance (AGAR) – Gram Negative study



- $700 pa On-going Multi-centre study (>20 hospitals in all states and territories) to determine trends and prevalence of antibiotic resistance

Australian Group for Antimicrobial Resistance (AGAR) – Pneumococcal study



- $500 pa On-going Multi-centre study (>20 hospitals in all states and territories) to determine trends and prevalence of antibiotic resistance

Community acquired bacteraemia

T Gottlieb 1999-2001 Multicentre collection of data on Community-acquired bacteraemia in Australian teaching hospitals

Multi-Centre Evaluation of Rapid Commercial Tests for the Diagnosis of Clostridium difficile

S Siarakas T Gottlieb et al.

Multiple company sponsorship: (including reagents for ELISA kits)

2001 $20,000 12 months To evaluate new toxin testing kits that can detect new variant strains of Clostridium difficile responsible for nosocomial infection outbreaks and death

The Role of Clostridium perfringens in Nosocomial and Community diarrhoea (Supervised Honors Project)

S Siarakas J Santos H Agus

Company sponsorship. The University of Sydney, Concord Microbiology Dept. ResearchTrust Fund

2001

$ 5,000 $ 600

12 months To identify if C. perfringens causes significant nosocomial diarrhoea as compared to the community

Clostridium difficile: Living in the Variant Era (Supervised Honors Project)

S Siarakas A. Kewley P Lorentzos H Agus

The University of Sydney, Concord Microbiology Dept. ResearchTrust Fund

2002 $ 1,000 $ 800

12 months To provide the first Australian data on the incidence of variant C. difficile strains. The bacteria are typed to determine if we share international types or types that are uniquely Australian

10

Role of Novel Antibiotics against Clostridium difficile

M Leroi S Siarakas T Gottlieb

Concord Microbiology Dept. Research Trust Fund. Company Sponsorship (Pharmacia, Bayer for sens strips)

2001 $ 600 $ 4,000

3 months The aim of this research is to determine the usefulness of some of the newer available antibiotics in C. difficile infection

Linezolid vs. Vancomycin/ Oxacillin in Gram Positive Cannula related sepsis

T Gottlieb M Peters

Pharmacia 2002 Nil todate

1 year This study will trial a treatment for patients with catheter-related bloodstream infections caused by gram positive pathogens

Australian Candidemia study

T Gottlieb Nil 3 years A multicentre evaluation of candidemia in Australia

Phenotypic and Genotypic studies of Staphylococcus aureus (non-multidrug and multidrug resistance MRSA) isolates in CSAHS

J Merlino R Bradbury T Gottlieb C Harbour B Rose J Watson

The University of Sydney

2000-2001 $15,000 Ongoing This research aims to track transmission of existing “golden staphylococci” in Hospitals and the community in CSAHS and detect emergence of new types of resistance with potentials to become epidemic

Surveillance and evaluation of new detection and isolation methods for Staphylococcus aureus (non-multidrug and multidrug resistance MRSA) in CSAH

J Merlino R Bradbury T Gottlieb C Harbour B Rose J Watson

University of Sydney Various companies- donation of kits

2001-2002 $5, 000$5, 000

Ongoing Genotypic and phenotypic studies to evaluate the expression of methicillin/oxacillin resistance in Staphylococcus aureus (non-multidrug and multidrug resistance) in CSAHS in order to improve antibiotic treatment outcomes

Detection of Extended Spectrum Beta-Lactamases in Gram-negative Bacilli at CRGH

M Poyten J Merlino T Gottlieb

Various companies - donations of kits etc.

2001-2002 $6,000 Ongoing Studies evaluating detection of bacterial resistance to 3rd and 4th Generation cephalosporins in Gram-negative bacteria

Coxiella burnetii in cats in Sydney – a serological survey

T Gottlieb M Leroi Concord Animal Hospital

Concord Microbiology Dept. ResearchTrust Fund

2001 $1,000 6 months Serological surveillance for incidence of C.burnetti antibodies in cat population in Sydney as a risk for urban Q fever

11

Moxifloxacin susceptibility in respiratory isolates – Multicentre study


Bayer 2001 $1,500 Complete Susceptibility testing of respiratory isolates to new generation fluoroquinolones – Multicentre study

Neurobiology Genetic Basis for Charcot-Marie-Tooth and Hereditary Sensory Neuropathy type I

G Nicholson M Kennerson

NH&MRC 2001 $615,000 3 years To identify the gene mutation causing dominant intermediate Charcot-Marie-Tooth neuropathy. To understand the disease mechanism causing hereditary sensory neuropathy type I

Finding the gene for hereditary sensory neuropathy


Rebecca L. Cooper 2001 $16,000 1 year To identifiy the gene causing hereditary sensory neuropathy type I

Functional studies on the gene causing hereditary sensory neuropathy


Clive and Vera Ramaciotti Foundation

2001 $12,500 1 year To develop a mouse model for hereditary sensory neuropathy type I

Mapping the mutation for hereditary sensory neuropathy

G Nicholson USA Muscular Dystrophy Association

1999 $49,818 3 year (US)

To screen candidate genes for mutations causing hereditary sensory neuropathy type I

Gene mutation analysis in Parkinson’s disease using real time PCR


Clive and Vera Ramaciotti Foundation

2002 $15,000 1 year To mutation screen Parkinson’s disease genes in a cohort of Australian patients using real time PCR (polymerase chain reaction)

Identifying new gene mutations for motor neurone disease

G Nicholson The Amyotrophic Lateral Sclerosis Association USA

2002 $49,071 3 year (US)

To identify new genes for motor neurone disease using genetic linkage studies

Molecular genetics of spinal cord neuropathies


Department of Medicine The University of Sydney

2002 $50,000 1 year To perform a genome screen on a large family with spinal cord neuropathy

Neurology PROGRESS A Corbett Servier and MRC

New Zealand 1996 $45,000 6 years This study looked at the lowering of blood pressure

with Perindopril and Indapamide for secondary stroke prevention. Study (completed and published 2001) showed a 28% risk reduction for recurrent stroke

12

TRANSCEND and ON TARGET

A Corbett Boehringer Ingleheim/Canadian Cardiovascular Collaboration Project Office

2002 $2,000(US) per patient

6 years A study of the relative effectiveness of an ACE inhibitor (Ramipril) and an Angiotensin 2 receptor antagonist (Telmisartan) for secondary prevention of vascular complications and death in patients with stroke, coronary artery disease, diabetes and peripheral vascular disease

A multi-centre, multinational, Phase 3, randomised, double blind, double-dummy, 3-arm parallel group, placebo- and ropinirole-controlled trial of the efficacy and safety of rotigotine CDS patch in subjects with early stage, idiopathic Parkinson disease

M Hayes Schwarz Pharma 2002 $50,000 1 year This study trials rotigotine CDS, a skin patch for delivery of a new Dopamine agonist Rotigotine in patients with early Parkinson disease

A phase 3, double blind, placebo controlled, randomised study comparing the efficacy, safety and tolerability of sumanirole versus placebo or ropinirole, as an adjuvant to levodopa, in patients with advanced Parkinson disease

M Hayes Pharmacia 2002 $50,000 1 year This is a trial of a new Dopamine agonist medication for treatment of advanced Parkinsons disease

DEDCEL M Hayes A Corbett

Brain Foundation 2001 $75,000 3 years Multicentre study of the relatives of patients with Parkinson disease to determine the utility of blood tests and MRI scan for the early detection of Parkinsons disease

Botulinum toxin and lower limb spasticity following stroke

M Hayes Allergon 1997 $5,000 5 year Treatment of patients with lower limb spasticity following stroke with botulinum toxin injection to reduce spasticity

13

Priority Health Care Program – Stroke

A Corbett J Watson J Cullen S Allen

Department of Health

2001 3 years This study aims to strengthen multidisciplinary management of in-patient care in all acute care and rehabilitation facilities in CSAHS. The research also aims to reduce crisis readmissions and enhance patient quality of life through better information, communication, risk identification and coordination of health services

Neurosurgery A prospective, randomised, double-blind trial to evaluate the efficacy of analgesic epidural paste in lumbar disc surgery

N Dan N Kazemi

This is a trial of an epidural paste for the control of post-operative pain following lumbar surgery

Nursing Discharge Planning from the perspective of patients and their family/carer

J Randall L Chenoweth C Luck C Smith C Fennell

The Association of Discharge Planning Nurses Inc.

February 2002

$3,000 I year This study aims to gain patients and their family/carer’s perspective of discharge planning at C.R.G.H. The findings will assist in evaluating the service that C.R.G.H. provides and identify areas within the system that can be improved

Extraventricular drains – sterile versus aseptic technique

V Sutherland D Lear

Research Centre for Adaptation in Health and Illness, The University of Sydney

2002 $1,500 1 year This research aims to establish best practice for the care of the neurologically-impaired patient who has an extraventricular drain (EVD) in situ and to standardise management of patients with EVDs

The implementation of the Family needs Protocol to assist nurses in addressing the needs of the family members of critically ill patients

G Glynn Research Centre for Adaptation in Health and Illness, The University of Sydney

2002 1 year The aims of this study are to reduce levels of anxiety in relatives of Intensive Care Unit (ICU) patients; to monitor relatives’ satisfaction with ICU services and to provide relevant education for ICU nurses that addresses the specific needs of relatives

14

Evaluation of a nurse-initiated discharge plan to improve the management of patients with asthma in the Emergency Department

J Munro M Richardson J O’Connell R Hawley


2002 $3 000 1 year This study investigates the effect of providing a nursing discharge plan and asthma education for patients with asthma who are discharged home from the Concord Emergency Department

Nutrition and Dietetics Investigation of the effects of charting high protein, high energy nutritional supplements on the outcomes of elderly hospitalised patients at risk of malnutrition

P MacLennan K Jukkola A Thornton N Czinner J Ravens

Research Centre for Adaptation in Health & Illness, The University of Sydney

2002 $3,500 1 year Through the use of a validated Nutrition screening and assessment tool this study aims to identify patients at risk of malnutrition, in order to prioritise dietetic treatment for those at greatest risk Through the use of a nutrient dense product dispensed during medication rounds in place of standard supplements given at midmeals, it is hoped to improve patient supplement compliance, in order to improve nutritional status, and patient outcomes

Investigation into the effect of Nutrition Intervention in long-term chemotherapy patients

N Crockett P Beale J Jacquet P MacLennan

Research Centre for Adaptation in Health & Illness, The University of Sydney

2002 $3,500 1 year Through the use of a validated nutrition screening tool (PG-SGA), this study aims to identify chemotherapy out-patients who require nutrition intervention on commencing treatment in MODU at CRGH

Diarrhoea incidence in burns patients in the Burns Unit at Concord Hospital – possible aetiological mechanisms and intervention

L Baytieh R Johnson P Maitz


2002 $3,200 1 year This study aims to see what factors are associated with diarrhoea that is commonly found in burns patients. Patients with Clostridium difficile infection will be either given Yoghurt containing a beneficial (probiotic) bacteria or trialled with a fibre solution, to test whether this will reduce the diarrhoea

Oncology NSABP C-07 trial P Beale

S Clarke A Sullivan

NSABP Nil to date - 3 years (ongoing)

Clinical trial of chemotherapy following surgery for bowel cancer

Celecoxib/CPT11 Colo-rectal Phase II

P Beale S Clarke

Pharmacia Nil to date - 8 months (ongoing)

Clinical trial of clelecoxib (celebrex) with chemotherapy for patients with advanced colon or rectal cancer

15

ANZ0001 trial M Stockler

A Sullivan P Beale

ANZBCTG Nil to date - 3 years (ongoing)

Clinical trial of chemotherapy for women with advanced or metastatic breast cancer

BCIRG trials 005 & 006 A Sullivan P Beale

BCIRG 2002

$1,951 (US)

2 years (ongoing) Clinical trials of chemotherapy and antibody treatments for women following surgery for breast cancer

YM 598 prostate trial M Stockler M Boyer S Clarke P Beale

Yamanouchi Nil to date - 1 year (ongoing)

Clinical trial of a new drug with chemotherapy for men with advanced prostate cancer

Chrysin/CPT11 study P Beale S Clarke

Unfunded - - 1 year (ongoing) Clinical trial of a drug to prevent diarrhoea with chemotherapy for bowel cancer

ZEST study M Stockler NHMRC-CTC Nil to date - 2 years (ongoing) Clinical trial of antidepressant drug in advanced cancer patients

JMAT NSCLC

S Clarke M Millward P Beale

Eli Lilly 2001 2002

$2,508 $1,547

1 year (closed) Clinical trial of chemotherapy for patients with advanced lung cancer

AG3340 NSCLC S Clarke M Millward P Beale M Boyer

Agouron 2001 $6,189 18 Months (closed) (US)

Clinical trial of a new drug to prevent tumour spread in lung cancer patients

IBCSG Study 20 A Sullivan M Stockler

ANZBCTG 20012002

$37,000 $2,500

5 years (closed) Clinical trials of chemotherapy for women following surgery for breast cancer

IRESSA NSCLC S Clarke M Millward P Beale

Astra Zeneca 2001 $4,060 18 months (closed)

Clinical trial of a new drug with chemotherapy to prevent tumour growth in lung cancer patients

TAX 327 Prosate M Stockler M Boyer P Beale

Aventis 2002 $21, 230 2 years (ongoing)

Clinical trial of chemotherapy for men with advanced prostate cancer

Capecitabine TS study S Clarke P Beale

Unfunded - - 3 years (ongoing) Predicting toxicity from treatment for advanced bowel cancer

Cisplatin inpatient/outpatient study

M Stockler P Beale

Unfunded - - 3 years (ongoing) Trial to see if giving cisplatin chemotherapy is best done on inpatient or outpatient basis

16

Orthopaedics Early Prospective Detection of Bone Marrow/Fat Embolism after Joint Arthroplasy

W Bruce H Van der Wall

This study aimed to find a method of distinguishing fat/marrow embolism from thromboembolism in patients who have had major joint surgery

Ophthalmology Evaluation of dry eye tests in normal asymptomatic population

F Booth J George A Lee

Nil 1 year The aim of this study was to evaluate standard tests for dry eyes in normal asymptomatic individuals, age and sex-matched to the dry-eye database

Palliative Care Documentation of the Incidence of Malignant Ascites and the use of paracentesis and diuretics in current management of malignant ascites (Pilot Study)

G Aggarwal M Agar

Nil N/A N/A 1 year To assess the incidence of malignant ascites in the hospital setting, document current management practice with regard to paracentesis and diuretics, and assess the feasibility of using the McGill Quality of Life questionnaire and Numeric rating scales for symptom assessment

End of life decision-making in the care of the patient

G Aggarwal N Sathasivam C Wong

Nil N/A N/A 1year To assess the care of the dying patient in a hospital, and how health-care professionals’ decision-making may play a role in this last phase of life. Also to assess Not-for-resuscitation documentation, medication usage and interventions in this phase

Double-blind, double-dummy, randomised, parallel-arm equivalence study comparing Hydromorphone Hydrochloride extended-release capsules (HHER) with MS Contin Tablets, at a dose ratio of 1:7.5, in cancer or non-cancer patient with a history of moderate to severe pain

G Aggarwal (multicentre)

Pharmaceutical Company Sponsored


6 months To establish whether HHER capsules and MS Contin tablets are equivalent

17

Database of patients using strong opioids for non-cancer pain

P Glare G Aggarwal

2002 Nil Years unspecified To establish a database of patients with non-cancer pain using strong opioids, treated in Central Sydney Area Health Service for long term evaluation

Prevalence of pain in a teaching hospital

G Aggarwal A Koutantos

Nil N/A N/A 9 months To record the prevalence of pain at Concord Hospital. Correlation will be made to mechanism of pain, staff awareness of pain and the adequacy of analgesics used. The Brief Pain Inventory will be used to assess functional impact of pain

Communication of prognostic information in palliative medicine – an analysis of audiotaped doctor/patient consultations

J Clayton P Butow M Tattersall R Chye G Aggarwal

NHMRC Medical/Dental Research Scholarship

2001 1 year To establish current practice in the communication of prognostic information to patients during palliative medicine consultations

Pain in hospitalised patients with cancer: prevalence, clinical characteristics, impact on quality of life and barriers to treatment

P Glare J Yip G Aggarwal

Nil N/A N/A 3 months To assess the prevalence, clinical characteristics, impact on quality of life and barriers to treatment of pain with cancer

Piloting a question prompt sheet for palliative care patients and subsequently conducting a randomised controlled trial of the question prompt sheet

J Clayton M Tattersall P Butow G Aggarwal

NHMRC medical postgraduate scholarship

2002 2 years To evaluate the use of the developed question Prompt Sheet on clinical practice. To pilot the developed QPS in new patients seeing a palliative care doctor and to evaluate the final QPS on clinical practice via a randomised trial

Physiotherapy Quality Improvement Project to review outcome measures post upper and lower abdominal surgery

Y Silva F Li

Nil 1 year The aim was to determine the most appropriate clinical indicator for patients who have undergone abdominal surgery and analyse in more detail the data collected

A trial into the effectiveness of soft tissue massage in the treatment of shoulder pain

P van den Dolder M Kwan

Nil 1 year(ongoing)

The aim of the study is to compare the efficacy of physiotherapy approach to the treatment of shoulder pain - namely specific massage around the shoulder

18

Exercise or advice for sub-acute low back pain?

K Refshauge C Maher L Barnsley L Pengel

NHMRC Australasian Physiotherapy low back trial consortium

2000-02 2000-01

$230,000 $120,000

2000-2002 The aim of the project is to evaluate the benefit of two different treatments for patients who have subacute low back pain

Forces and frequencies used in percussion and vibration techniques

F Li Y Silva

Nil 1 year The aim of this study was to identify the force and frequency applied by physiotherapists when using percussion and vibration techniques on subjects using different layers of towelling

The effectiveness of pulmonary rehabilitation on patients post lung resection

Y Silva F Li M Peters

Nil 18 months The aim of this project was to evaluate the benefit of a pulmonary rehabilitation program on a group of patients post lung surgery compared to a group of patients who continued with their normal activities

Multi-centre trial of a revised version of the Elderly Mobility Scale; a retrospective study

F Li V Graham N Buckley D Delaney A. Karkovic

Nil 3 years The aim of the project is to validate a new functional measurement scale, a modified version of the Elderly Mobility scale (version 3) against existing scales. The scale is used to record functional measures of inpatients on admission and at discharge

Psychological Medicine The behavioural and neurotoxic effects of MDMA (“Ecstasy”)

I McGregor G Hunt

NH&MRC 2001 $53,000per year

3 years To examine the behavioural and neurotoxic effects of Ecstasy in animal models

Psychology Cognitive behavioural treatment of panic disorder

F Kemp F Wilkinson

RCAHI seeding grants scheme

2001 $4,291 18months To compare 2 treatment components of cognitive behaviour therapy for panic disorder

Comparison of patients’ psychological state attending cardiac rehabilitation with those patients receiving “normal” discharge care

P Mangioni RCAHI seeding grants scheme

2001 $4,600 18 months Assessment of psychological state of patients who attend cardiac rehabilitation in comparison to those who receive “normal” discharge care

Rheumatology Low level laser for neck pain

R Chow L Barnsley

Nil Effects of low level laser therapy on chronic neck pain

19

Outcomes of radiofrequency denervation for chronic neck pain

L Barnsley Nil Follow up study of patients having a nerve cooking procedure for control of chronic neck pain

Remicade for Rheumatoid arthritis

L Barnsley Sponsoring company

2002 2 years Effects of a new biological agent on Rheumatoid arthritis

Speech Pathology The effect of chronic obstructive pulmonary disease (COPD) on laryngo-pharyngeal sensitivity (LPS) and dysphagia

N Clayton A Ing M Peters G Mann

Nil 2 years To determine the prevalence of LPS impairment in patients with smoking-related COPD

Thoracic Medicine A comparison of treatment with 250µg roflumilast versus 500µg roflumilast versus placebo over 24 weeks in patients with chronic obstructive lung disease (COPD)

S Lim M Peters L Seeto L Plowman

Byk Gulden, Altana Pharma


8 months A study to assess the efficacy of a phosphodiesterase 4 inhibitor, roflumilast, in suppressing the inflammatory process in patients with obstructive lung disease

A phase III, 28 week, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of subcutaneous omalizumab initiated post hospitalisation or emergency room admission in adolescent and adult allergic asthmatics with a history of significant asthma exacerbations

S Lim L Plowman M Baraket M Peters L Seeto

Novartis 2002 ~$4000per patient

8 months

A study to evaluate the efficacy, safety and tolerability of subcutaneous omalizumab, a monoclonal antibody containing 95% human protein, in adolescent and adult allergic asthmatics with a history of significant asthma exacerbations. Omalizumab, by sticking to IgE antibodies, is thought to benefit asthma by reducing airway inflammation, thus decreasing asthma symptoms

20

The role of AKT in the molecular pathogenesis of Chronic Obstructive Pulmonary Disease (COPD)

L Seeto S Lim

2001 Ongoing This study aims to determine whether, in Chronic Obstructive Pulmonary Disease (COPD), the intracellular enzyme AKT, governs: inflammation, white cell survival, enzymatic lung damage, innate immunity in COPD exacerbations and inactivation of steroid receptors

Alveolar macrophage expression of p21 in Chronic Obstructive Pulmonary Disease (COPD)

L Seeto S Lim

2001 Ongoing This study looks at the expression of p21, a key protein in controlling the cell cycle, in alveolar macrophages from patients with COPD, and to correlate this expression with persistence of inflammation

The effect of inhaled corticosteroids in COPD, a double blind parallel group study of inhaled steroid withdrawal in patients with COPD

M Baraket S Lim

2001 Ongoing This study investigates the effectiveness of using inhaled corticosteroids in COPD, by assessing objective parameters such as lung function tests and inflammatory markers, as well as subjective results including personal diaries and quality of life questionnaires

The expression of matrix metalloproteinases (MMPs) and cytokines from alveolar macrophages in Chronic Obstructive Pulmonary Disease (COPD): The effect of oral theophylline in COPD, a randomised double blind placebo controlled study in patients with COPD

L Seeto S Lim

Mitsubishi 2001 $30,000(approx)

2 years This study aims to determine whether sub-bronchodilating doses of theophylline have an anti-inflammatory effect in patients with COPD

21

The expression of matrix metalloproteinases (MMPs) and cytokines from alveolar macrophages in Chronic Obstructive Pulmonary Disease (COPD): The effect of inhaled steroids in COPD, a double-blind placebo controlled study in patients with COPD

L Seeto S Lim

Smoking is harmful in many ways and this study aims to investigate if there is an overproduction of cytokines and matrix- metalloproteinases (MMPs) from alveolar macrophages in the 15% of smokers who develop COPD. The study also examines the effects of inhaled steroids on the production of MMPs and cytokines in patients with COPD

Risk factors for developing hypoxia during air travel in passengers with lung disease

L Seccombe 2002

Study on the etiology of community-acquired pneumonia in patients admitted to Concord Hospital

M Comsa 2002

A study to examine the effects of environment (aeroallergens) on nocturnal asthma using an automated wheeze quantification device (PulmoTrack)

G Cossa 2001 12 months Nocturnal wheeze disturbs 70-80% of all asthmatics, and is most likely due to allergen exposure. This study aims to investigate the effects of sleeping environment in patients with nocturnal symptoms of asthma, by comparing measures of nocturnal wheezing with measures of temperature, humidity and airborne allergens in the home and Sleep Study Unit environments

22

Efficacy and safety of 5 days oral telithromyocin (HMR3647 – 800mg once daily) versus 10 oral clarithromycin (500mg twice daily) in the treatment of acute exacerbation of chronic bronchitis (AECB)

M Peters Aventis Pharma 2001 funding ongoing

$5000 per

patient

6 months A study to assess the efficacy and safety of 5 days of oral telithromycin in the treatment of an acute exacerbation of chronic bronchitis, compared with an accepted treatment of 10 days of oral clarithromycin

Efficacy and safety of symbicort turbuhaler as single therapy in patients with moderate- severe asthma. Comparison with conventional therapy, Pulmicort (budesonide) turbuhaler as maintenance treatment complemented with Bricanyl (terbutaline) turbuhaler

M Peters L Morgan

AstraZeneca 2001funding ongoing

$3 689 per

patient

1 year A study to assess the efficacy and safety of Symbicort (budesonide/ formoterol) turbuhaler as a single therapy in patients with moderate-severe asthma, compared with conventional therapy, Pulmicort (budesonide) turbuhaler complemented with Bricanyl (terbutaline) turbuhaler

Metered dose inhaler (MDI) assessment in subjects with chronic obstructive pulmonary disease (COPD) or asthma

K Wade L Plowman

2001 Ongoing Some drugs, used in the treatment of inflammation or bronchoconstriction in people with COPD or asthma, are delivered using inhalation devices, including a metered dose inhaler. The correct technique for the use of MDIs requires good coordination between breathing and the hand. Without such coordination drug delivery is poor. This study assesses the MDI technique of patients from outpatient clinics at Concord Hospital to determine whether further patient education is required or not

23

The Role of Neurotrophins in chronic idiopathic cough

A Ing B Rost S Lim

2002 This study investigates the role of inflammatory proteins in the origin of chronic cough of unknown cause in otherwise healthy people

The molecular mechanisms of corticosteroid action (in vivo and in vitro) in asthmatic inflammation and the regulation of IL-15 production by alveolar macrophages and respiratory epithelium by IL-14 and rhinovirus infection

M Baraket S Lim B Oliver

2002 This study aims to examine the effects of inhaled corticosteroids on airway inflammation in patients with mild-moderate asthma, looking in particular at cytokines from alveolar macrophages. A secondary aim is to study in vitro the effects of viral infection and the influences of respiratory viruses upon cytokine production

Urology Ultrastructural Basis of Voiding Dysfunction (Correlation of Gap Junctional Protein Expression and Ultrastructural Features in the Unstable Human Detrusor)

V Tse L Chan J Yin C McLachlan E Wills S Brammah

Abbot Australasia Institute of Urology, CSAHS

2001 $12,000 Ongoing The aim is to investigate the ultrastructural changes in the bladder of patients with overactive bladder causing symptoms of frequency, urgency and urge incontinence. We have demonstrated the existence of abnormal junctions between the bladder muscle cells in these patients. Currently we are investigating the nature of these junctions to better understand this common condition and to develop new treatment strategies

GUOG – A Phase II Study to Assess the Effect of Intermittent Androgen Blockade in the treatment of advanced prostate cancer

A Lalak L Chan A Mitterdorfer D Vasilareas N Hanly

Schering Plough 2001 $400 per patient

Ongoing until August 2004

To investigate the quality of life and treatment effects of hormone treatment for advanced prostate cancer given on an intermittent basis. This is a nation-wide study conducted by the Genito-Urinary Oncology Group

24

25

A randomised, double-blind, parallel group, placebo and active controlled, multi-centre study of YM905 5 mg and 10 mg in patients with overactive bladder

L Chan D Eisinger A Mitterdorfer J Rogers D Vasilareas N Hanly

Yamanouchi 2001 ~$2,600per patient

June 01 – January 02

YM905 is a new drug that Yamanouchi Europe BV has developed for the treatment of patients with symptoms of urinary frequency, urgency and/or urge incontinence (also called “overactive bladder”). YM905 is a tissue selective M3 cholinoceptor antagonist. This is multi centre international trial to assess the effect, safety and tolerability of YM905 in patients with an overactive bladder

An open-label, long-term safety and efficacy follow-up study of YM905 5mg and 10mg in patients with overactive bladder

L Chan D Eisinger A Mitterdorfer J Rogers D Vasilareas N Hanly

Yamanouchi 2001 ~$2,600per patient

December 01 – October 02

This is an open label extension study to assess the long term safety, tolerability and effect of YM905 in the treatment of patients with an overactive bladder over a 9 month period

PFIZER STUDY A2841023 UK-338,003 IN BENIGN PROSTATIC OBSTRUCTION

L Chan D Vasilareas N Hanly

Pfizer Pty Ltd 2002 ~$3,000 per patient

April 02 – October 02

UK338,003 is a drug developed by Pfizer to treat patients with symptoms of benign prostatic obstruction. It is a prostate selective alpha-blocker. This a multi-centre international trial to assess the effect, safety and tolerability of UK338,003

TRIUMPH Study A Lalak A Mitterdorfer P Maher N Hanly

Yamanouchi 2002 $500 perpatient

January 01- March 02

Triumph is a multi-centre international trial looking at the way in which patients with Benign Prostatic Hyperplasia are managed and offered treatment (a pattern of care study)

Patients experience of Urodynamics and Prostate Biopsy

J Medd A Lalak L Chan P Maher M Stockler

None Nil Nil 2001 The aim of the study was to develop a questionnaire to be used to evaluate patients’ experience of prostate biopsy and video urodynamics, two of the most common investigations of the urinary tract. The study also looked at whether psychological and or medical interventions to relieve any distress during the procedures would be of benefit

facility: concord hospital · induced by ttp-based cationic lipophilic phosphonium salts (clps) and...

Documents